Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

A phase I/II, open label, Study to evaluate safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis: Interim report of phase I results

View Full Paper
Ask AI
Bookmark
Share

Authors

SHShahrier HossainASAdam S. SperlingBFBrendan Fink

Discussion

Loading...

Member takes

Overview

Interim report shows elranatamab achieves 100% overall response in relapsed AL amyloidosis with mild cytokine release syndrome.

Key Points

  • Elranatamab resulted in complete responses for all patients, indicating promising efficacy in treating AL amyloidosis.
  • All enrolled patients achieved rapid normalization of free light chains below 10 mg/L by cycle 2 day 1.
  • This phase I clinical trial confirmed elranatamab's safety profile, with manageable adverse events during treatment.
  • Findings highlight elranatamab's potential role in managing relapsed AL amyloidosis and warrant further investigation.

Cite This Study

Hossain et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236de30https://doi.org/10.1182/blood-2025-5808
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Population Exposure–Response Efficacy Analysis of Elranatamab (PF-06863135) in Patients with Multiple Myeloma2025 · 7 citations
  2. 2Real-world outcomes of elranatamab in relapsed/refreactor multiple myeloma: A single center analysis2025
  3. 3Phase 1/2 dose escalation and expansion study of etentamig in patients with relapsed or refractory light chain amyloidosis2025 · 3 citations
  4. 4Talquetamab induces deep responses in heavily pre-treated patients with systemic light-chain amyloidosis2025
  5. 5ALACRITY: A phase 1b/2 study of AZD0120 (BCMA/CD19 CAR-T cell therapy) in participants with relapsed or refractory light chain amyloidosis (AL)2025